129 related articles for article (PubMed ID: 36230514)
1. Comment on Kieslinger et al. A Recurrent
Freiche V; Couronné L; Bruneau J; Hermine O
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230514
[TBL] [Abstract][Full Text] [Related]
2. A Recurrent
Kieslinger M; Swoboda A; Kramer N; Freund P; Pratscher B; Neubauer HA; Steinborn R; Wolfesberger B; Fuchs-Baumgartinger A; Moriggl R; Burgener IA
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680385
[TBL] [Abstract][Full Text] [Related]
3. Structural and functional consequences of the STAT5B
de Araujo ED; Erdogan F; Neubauer HA; Meneksedag-Erol D; Manaswiyoungkul P; Eram MS; Seo HS; Qadree AK; Israelian J; Orlova A; Suske T; Pham HTT; Boersma A; Tangermann S; Kenner L; Rülicke T; Dong A; Ravichandran M; Brown PJ; Audette GF; Rauscher S; Dhe-Paganon S; Moriggl R; Gunning PT
Nat Commun; 2019 Jun; 10(1):2517. PubMed ID: 31175292
[TBL] [Abstract][Full Text] [Related]
4. Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia.
Cross NCP; Hoade Y; Tapper WJ; Carreno-Tarragona G; Fanelli T; Jawhar M; Naumann N; Pieniak I; Lübke J; Ali S; Bhuller K; Burgstaller S; Cargo C; Cavenagh J; Duncombe AS; Das-Gupta E; Evans P; Forsyth P; George P; Grimley C; Jack F; Munro L; Mehra V; Patel K; Rismani A; Sciuccati G; Thomas-Dewing R; Thornton P; Virchis A; Watt S; Wallis L; Whiteway A; Zegocki K; Bain BJ; Reiter A; Chase A
Leukemia; 2019 Feb; 33(2):415-425. PubMed ID: 30573779
[TBL] [Abstract][Full Text] [Related]
5. A case of hypereosinophilic syndrome with STAT5b N642H mutation.
Ding F; Wu C; Li Y; Mukherjee S; Ghosh S; Arrossi AV; Krishnan S
Oxf Med Case Reports; 2021 Jan; 2021(1):omaa129. PubMed ID: 33542831
[TBL] [Abstract][Full Text] [Related]
6. The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse.
Bandapalli OR; Schuessele S; Kunz JB; Rausch T; Stütz AM; Tal N; Geron I; Gershman N; Izraeli S; Eilers J; Vaezipour N; Kirschner-Schwabe R; Hof J; von Stackelberg A; Schrappe M; Stanulla M; Zimmermann M; Koehler R; Avigad S; Handgretinger R; Frismantas V; Bourquin JP; Bornhauser B; Korbel JO; Muckenthaler MU; Kulozik AE
Haematologica; 2014 Oct; 99(10):e188-92. PubMed ID: 24972766
[No Abstract] [Full Text] [Related]
7. STAT5BN642H is a driver mutation for T cell neoplasia.
Pham HTT; Maurer B; Prchal-Murphy M; Grausenburger R; Grundschober E; Javaheri T; Nivarthi H; Boersma A; Kolbe T; Elabd M; Halbritter F; Pencik J; Kazemi Z; Grebien F; Hengstschläger M; Kenner L; Kubicek S; Farlik M; Bock C; Valent P; Müller M; Rülicke T; Sexl V; Moriggl R
J Clin Invest; 2018 Jan; 128(1):387-401. PubMed ID: 29200404
[TBL] [Abstract][Full Text] [Related]
8. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia.
Rajala HL; Eldfors S; Kuusanmäki H; van Adrichem AJ; Olson T; Lagström S; Andersson EI; Jerez A; Clemente MJ; Yan Y; Zhang D; Awwad A; Ellonen P; Kallioniemi O; Wennerberg K; Porkka K; Maciejewski JP; Loughran TP; Heckman C; Mustjoki S
Blood; 2013 May; 121(22):4541-50. PubMed ID: 23596048
[TBL] [Abstract][Full Text] [Related]
9. Rare occurrence of a STAT5B N642H mutation in adult T-cell acute lymphoblastic leukemia.
Ma X; Wen L; Wu L; Wang Q; Yao H; Wang Q; Ma L; Chen S
Cancer Genet; 2015; 208(1-2):52-3. PubMed ID: 25749351
[No Abstract] [Full Text] [Related]
10. Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial.
Auclin E; Mezquita L; Besse B
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298837
[TBL] [Abstract][Full Text] [Related]
11. JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 Inhibitors.
Govaerts I; Jacobs K; Vandepoel R; Cools J
Hemasphere; 2019 Dec; 3(6):e313. PubMed ID: 31976485
[No Abstract] [Full Text] [Related]
12. Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells.
Küçük C; Jiang B; Hu X; Zhang W; Chan JK; Xiao W; Lack N; Alkan C; Williams JC; Avery KN; Kavak P; Scuto A; Sen E; Gaulard P; Staudt L; Iqbal J; Zhang W; Cornish A; Gong Q; Yang Q; Sun H; d'Amore F; Leppä S; Liu W; Fu K; de Leval L; McKeithan T; Chan WC
Nat Commun; 2015 Jan; 6():6025. PubMed ID: 25586472
[TBL] [Abstract][Full Text] [Related]
13. Comment on Lionte et al. Association of Multiple Glycemic Parameters at Hospital Admission with Mortality and Short-Term Outcomes in Acutely Poisoned Patients.
Ferrés-Padró V; Solà-Muñoz S; Jiménez-Fàbrega FX; Nogué-Xarau S
Diagnostics (Basel); 2021 Jun; 11(6):. PubMed ID: 34205003
[TBL] [Abstract][Full Text] [Related]
14. Chronic eosinophilic leukemia with recurrent STAT5B N642H mutation-An entity with features of myelodysplastic syndrome/ myeloproliferative neoplasm overlap.
Sreedharanunni S; Jamwal M; Balakrishnan A; Aravindan AV; Sharma R; Singh N; Rajpal S; Singla S; Khadwal AR; Ahluwalia J; Malhotra P; Das R
Leuk Res; 2022 Jan; 112():106753. PubMed ID: 34856508
[No Abstract] [Full Text] [Related]
15. Comment on Roelofs, K.A.; et al. Detecting Progression of Melanocytic Choroidal Tumors by Sequential Imaging: Is Ultrasonography Necessary?
Capasso L; Gioia M; De Bernardo M; Rosa N
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804046
[TBL] [Abstract][Full Text] [Related]
16. Comment on Ibrahim et al. The Effects of In-Plane Spatial Resolution on CT-Based Radiomic Features' Stability with and without ComBat Harmonization.
Orlhac F; Buvat I
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34207102
[TBL] [Abstract][Full Text] [Related]
17. Comment on: Malfitano, A.M. et al. "Virotherapy as a Potential Therapeutic Approach for the Treatment of Aggressive Thyroid Cancer"
Alberts P
Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 31978984
[TBL] [Abstract][Full Text] [Related]
18. Creating Opportunities to Eliminate Disparities in Lung Cancer Outcomes: A Call for Diverse Study Populations. Comment on Kohan et al. Disparity and Diversity in NSCLC Imaging and Genomics: Evaluation of a Mature, Multicenter Database.
Washington CJ; Braithwaite D
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568577
[TBL] [Abstract][Full Text] [Related]
19. Serum haptoglobin concentrations in feline inflammatory bowel disease and small-cell alimentary lymphoma: a potential biomarker for feline chronic enteropathies.
Love EK; Leibman NF; Ringold R; Lamb K
J Feline Med Surg; 2021 Oct; 23(10):959-964. PubMed ID: 33541236
[TBL] [Abstract][Full Text] [Related]
20. Feline low-grade alimentary lymphoma: an emerging entity and a potential animal model for human disease.
Paulin MV; Couronné L; Beguin J; Le Poder S; Delverdier M; Semin MO; Bruneau J; Cerf-Bensussan N; Malamut G; Cellier C; Benchekroun G; Tiret L; German AJ; Hermine O; Freiche V
BMC Vet Res; 2018 Oct; 14(1):306. PubMed ID: 30305106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
